Enhancement Radiosensitization of Breast Cancer Cells by Deguelin
- 1 June 2008
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 23 (3) , 355-362
- https://doi.org/10.1089/cbr.2007.0452
Abstract
Objective: Radiation can activate the phosphatidylinositol 3-kinase/Akt pathway and cannot downregulate survivin expression in breast cancer cells. Deguelin induces apoptosis in breast cancer cells by inhibiting pAkt and survivin expression. In this study, we assessed the effect of deguelin on radiosensitization of human breast cancer cells and its possible mechanism. Methods: Deguelin and radiation were administrated in MDA-MB-231 human breast cancer cells. The cytotoxic interactions and mutual influences between these 2 modalities were analyzed by a series of assays including clonogenic, flow cytometric, and Western blotting. Results: Phospho-Akt expression and survivin expression significantly decreased after 10 nM deguelin treatment, while phospho-Akt expression increased and survivin expression did not alter after radiation (3 Gy). However, phospho-Akt expression and survivin expression further significantly decreased after deguelin combined with radiation treatment. Deguelin combined with radiation markedly decreased clonogenic cell survival. After treatment of deguelin (10 nM) combined with radiation (3 Gy), caspase-dependent apoptosis was significantly increased and cell cycle was arrested in the G2-M phase in MDA-MB-231 cells. Conclusions: Deguelin attenuates radiation-induced prosurvival Akt signaling and enhances the radiosensitivity of MDA-MB-231 cells, and the mechanisms for this action may include inhibiting phospho-Akt and survivin expression, increasing caspase-dependent apoptosis, and prolonging cell cycle arrest in the G2-M phase.Keywords
This publication has 24 references indexed in Scilit:
- Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cellsInternational Journal of Radiation Oncology*Biology*Physics, 2006
- PI3K/Akt/mTOR pathway as a target for cancer therapyAnti-Cancer Drugs, 2005
- Cancer incidence and mortality in Europe, 2004Annals of Oncology, 2005
- S22 Which extent of Adjuvant Radiotherapy is Standard?The Breast, 2005
- Radioresistance in carcinoma of the breastThe Breast, 2004
- Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical PracticeCancer Research, 2004
- An IAP-IAP Complex Inhibits ApoptosisJournal of Biological Chemistry, 2004
- HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsOncogene, 2003
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- The protein kinase B/Akt signalling pathway in human malignancyCellular Signalling, 2002